234 related articles for article (PubMed ID: 32983280)
21. Nanomedicines: The magic bullets reaching their target?
Flühmann B; Ntai I; Borchard G; Simoens S; Mühlebach S
Eur J Pharm Sci; 2019 Feb; 128():73-80. PubMed ID: 30465818
[TBL] [Abstract][Full Text] [Related]
22. Commercial utilities and future perspective of nanomedicines.
Malviya R; Fuloria S; Verma S; Subramaniyan V; Sathasivam KV; Kumarasamy V; Hari Kumar D; Vellasamy S; Meenakshi DU; Yadav S; Sharma A; Fuloria NK
PeerJ; 2021; 9():e12392. PubMed ID: 34820175
[TBL] [Abstract][Full Text] [Related]
23. Next-generation nanomedicines and nanosimilars: EU regulators' initiatives relating to the development and evaluation of nanomedicines.
Ehmann F; Sakai-Kato K; Duncan R; Hernán Pérez de la Ossa D; Pita R; Vidal JM; Kohli A; Tothfalusi L; Sanh A; Tinton S; Robert JL; Silva Lima B; Amati MP
Nanomedicine (Lond); 2013 May; 8(5):849-56. PubMed ID: 23656268
[TBL] [Abstract][Full Text] [Related]
24. Challenges in nanomedicine clinical translation.
Metselaar JM; Lammers T
Drug Deliv Transl Res; 2020 Jun; 10(3):721-725. PubMed ID: 32166632
[TBL] [Abstract][Full Text] [Related]
25. Mapping of the available standards against the regulatory needs for nanomedicines.
Halamoda-Kenzaoui B; Holzwarth U; Roebben G; Bogni A; Bremer-Hoffmann S
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2019 Jan; 11(1):e1531. PubMed ID: 29923692
[TBL] [Abstract][Full Text] [Related]
26. Patented and Approval Scenario of Nanopharmaceuticals with Relevancy to Biomedical Application, Manufacturing Procedure and Safety Aspects.
Agarwal V; Bajpai M; Sharma A
Recent Pat Drug Deliv Formul; 2018; 12(1):40-52. PubMed ID: 29303083
[TBL] [Abstract][Full Text] [Related]
27. Transforming nanomedicine manufacturing toward Quality by Design and microfluidics.
Colombo S; Beck-Broichsitter M; Bøtker JP; Malmsten M; Rantanen J; Bohr A
Adv Drug Deliv Rev; 2018 Mar; 128():115-131. PubMed ID: 29626549
[TBL] [Abstract][Full Text] [Related]
28. Overview of the blood compatibility of nanomedicines: A trend analysis of in vitro and in vivo studies.
Urbán P; Liptrott NJ; Bremer S
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2019 May; 11(3):e1546. PubMed ID: 30556649
[TBL] [Abstract][Full Text] [Related]
29. [Early achievements of the Danish pharmaceutical industry--8. Lundbeck].
Grevsen JV; Kirkegaard H; Kruse E; Kruse PR
Theriaca; 2016; (43):9-61. PubMed ID: 27491172
[TBL] [Abstract][Full Text] [Related]
30. Regulatory challenges of nanomedicines and their follow-on versions: A generic or similar approach?
Mühlebach S
Adv Drug Deliv Rev; 2018 Jun; 131():122-131. PubMed ID: 29966685
[TBL] [Abstract][Full Text] [Related]
31. Nanomedicines: From Bench to Bedside and Beyond.
Havel H; Finch G; Strode P; Wolfgang M; Zale S; Bobe I; Youssoufian H; Peterson M; Liu M
AAPS J; 2016 Nov; 18(6):1373-1378. PubMed ID: 27480318
[TBL] [Abstract][Full Text] [Related]
32. Updated Regulatory Considerations for Nanomedicines.
Subin TS; Vijayan V; Kumar KJR
Pharm Nanotechnol; 2017; 5(3):180-191. PubMed ID: 28641516
[TBL] [Abstract][Full Text] [Related]
33. Industrial Scale Manufacturing and Downstream Processing of PLGA-Based Nanomedicines Suitable for Fully Continuous Operation.
Operti MC; Bernhardt A; Sincari V; Jager E; Grimm S; Engel A; Hruby M; Figdor CG; Tagit O
Pharmaceutics; 2022 Jan; 14(2):. PubMed ID: 35214009
[TBL] [Abstract][Full Text] [Related]
34. Regulation of nanomedicines in the EU: distilling lessons from the pediatric and the advanced therapy medicinal products approaches.
Chowdhury N
Nanomedicine (Lond); 2010 Jan; 5(1):135-42. PubMed ID: 20025470
[TBL] [Abstract][Full Text] [Related]
35. Towards a European strategy for medicines research (2014-2020): The EUFEPS position paper on Horizon 2020.
Gaspar R; Aksu B; Cuine A; Danhof M; Takac MJ; Linden HH; Link A; Muchitsch EM; Wilson CG; Ohrngren P; Dencker L
Eur J Pharm Sci; 2012 Dec; 47(5):979-87. PubMed ID: 23046836
[TBL] [Abstract][Full Text] [Related]
36. The potential anti-infective applications of metal oxide nanoparticles: A systematic review.
Abo-Zeid Y; Williams GR
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2020 Mar; 12(2):e1592. PubMed ID: 31595709
[TBL] [Abstract][Full Text] [Related]
37. Nanotherapeutics: An insight into healthcare and multi-dimensional applications in medical sector of the modern world.
Prasad M; Lambe UP; Brar B; Shah I; J M; Ranjan K; Rao R; Kumar S; Mahant S; Khurana SK; Iqbal HMN; Dhama K; Misri J; Prasad G
Biomed Pharmacother; 2018 Jan; 97():1521-1537. PubMed ID: 29793315
[TBL] [Abstract][Full Text] [Related]
38. Building the design, translation and development principles of polymeric nanomedicines using the case of clinically advanced poly(lactide(glycolide))-poly(ethylene glycol) nanotechnology as a model: An industrial viewpoint.
Lakkireddy HR; Bazile D
Adv Drug Deliv Rev; 2016 Dec; 107():289-332. PubMed ID: 27593265
[TBL] [Abstract][Full Text] [Related]
39. Herbal nanomedicines: Recent advancements, challenges, opportunities and regulatory overview.
Teja PK; Mithiya J; Kate AS; Bairwa K; Chauthe SK
Phytomedicine; 2022 Feb; 96():153890. PubMed ID: 35026510
[TBL] [Abstract][Full Text] [Related]
40. Safety and Toxicological Considerations of Nanomedicines: The Future Directions.
Patel P; Shah J
Curr Clin Pharmacol; 2017; 12(2):73-82. PubMed ID: 28486906
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
